|
| Exchange Received Time 09/12/2017 19:38:42 Exchange Disseminated Time 09/12/2017 19:38:45 Time Taken 00:00:03 | | The Board of Directors, at their meeting today, approved the unaudited Financial Results (Stand-alone & Consolidated) for the Quarter / Six-month ended September 30, 2017, which are attached herewith, along with Limited Review Reports, pursuant to Regulation 33 (3) (a) to (c) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board has decided to defer a decision on interim dividend pending assessment of requirement of funds to meet the capex requirements of the wholly-owned subsidiary, Nueclear Healthcare Limited, since the Company has already decided to give them loan to help them acquire costly equipment like Cyclotron, PET-CT Scan machines, etc., to set up additional scanning centres; to invest upto Rs. 20 crores in Equinox Labs Private Limited, Navi Mumbai-Rs. 10 crores in cash and by divestment of Water Testing Business to them for Rs. 10 crores, on slump sale basis, and to administer the ESOP schemes hereafter directly instead of through the Trust. |
|
|